Amgen’s focus on blood cell medications continued in the 2000s, with the approval of Aranesp for the treatment of anaemic patients with chronic renal failure, and the 2002 approval of Neulasta ...

Pegloticase therapy for uncontrolled gout does not appear to significantly increase the risk for cardiovascular (CV) or thromboembolic (TE) events, despite the potential for increased gout flares ...

We recently compiled a list of the 15 Best Biotech Stocks to Buy According to Billionaires. In this article, we are going to ...

inaxaplin for APOL1-mediated kidney disease and povetacicept for IgA nephropathy. Vertex could even cure severe type 1 diabetes with zimislecel. Magnificent growth stock? I think Vertex ...

Amgen has reported positive phase 3 results ... An e-Book aimed at children with rare kidney disease aHUS can help them understand the condition, deal with emotions, and find support, says Alexion.

Amgen’s discovery pipeline has led the company to broaden its focus from oncology, immunology, and renal disease to include musculoskeletal, cardiovascular, and neurologic conditions.

In early February, Amgen released financial results for the 4th quarter of 2024, which I was eagerly awaiting. In addition to demonstrating efficacy in the treatment of nasal polyps in Phase 3 ...

Amgen announced its plans to open a "technology and innovation" site in India last year that is focused on increasing the use of AI and data science to support development of new medicines.